On June 5, the Health Resources and Services Administration, part of the U.S. Department of Health and Human Services, published a final rule that further delays the effective date of the January 5, 2017 final rule on calculation of drug price ceilings and the imposition of civil monetary penalties for manufacturers that knowingly and intentionally overcharge covered entities under the 340B Drug Pricing Program.
Implementation of the price ceiling rule, discussed in detail here, had already been postponed four times, most recently last August. The effective date of the rule will now be further delayed until July 1, 2019, "to allow a more deliberate process of considering alternative and supplemental regulatory provisions and to allow for sufficient time for any additional rulemaking."
For more articles and regular updates on legislative changes, regulatory developments and other news of interest to businesses, professionals and investors in the healthcare industry, please subscribe to Day Pitney's mailing lists.
Click here for more Healthcare Blogs from Day Pitney
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
